ENTERA BIO LTD. Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement
ENTERA BIO LTD. (ENTX) had Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement of $4.36 as of 2018-12-31, per its 20-F filed 2019-03-28.
Discontinued › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement · last filed 2019-03-28
- 2018-12-31: Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement $4.36.
- 2017-12-31: Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement $4.59.
- 2016-12-31: Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement $1.43.
- 2015-12-31: Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement $0.92.
| Period end | Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement |
|---|---|
| 2018-12-31 | $4.36 20-F · filed 2019-03-28 |
| 2017-12-31 | $4.59 20-F · filed 2019-03-28 |
| 2016-12-31 | $1.43 20-F · filed 2019-03-28 |
| 2015-12-31 | $0.92 20-F · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |